Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Acasti Pharma Inc announces closing of $23 million underwritten offering of units


Tuesday, 3 Dec 2013 10:14am EST 

Acasti Pharma Inc:Says that the closing of its previously announced underwritten public offering of 16,000,000 units.Says at a price of $1.25 per Unit.Says each unit consisting of one Class A share and one Common Share purchase warrant.Says each warrant will entitle the holder to purchase one common share at an exercise price of $1.50 per warrant share.Says prior to the closing, the underwriters exercised their over-allotment option in full to purchase an additional 2,400,000 units, resulting in a total of 18,400,000 units being issued for gross proceeds of approximately $23 million.Says Euro Pacific Canada Inc. acted as book-running manager for the offering, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc., acted as co-manager.Says Roth Capital Partners, LLC acted as financial advisor for the offering and H.C. Wainwright & Co., LLC acted as advisor.Estimates that the net proceeds from the offering will be approximately $20.8 million, after deducting the underwriting commissions and other offering expenses.Says Acasti intends to allocate the net proceeds from the offering as current Phase II double blind clinical trial, proposed pharmacokinetic trial of CaPre in the United States and the balance for general corporate and other working capital purposes. 

Company Quote

0.5401
-0.0163 -2.93%
26 Dec 2014